Multiple Myeloma: Turn a Treatment Quote into an Itemized Budget You Can Check
When you receive a quote for myeloma treatment, first check its start date, starting stage, and endpoint. Then separate the costs of medicines, tests, supportive care, and care after returning home. Ask the hospital for a dated, itemized estimate based on your medical records. Mark items that are not yet confirmed as “to be determined,” rather than entering zero. Do not treat expected insurance reimbursement as money already received.
Key points
- Initial treatment, transplantation, relapse treatment, and CAR-T have different cost structures. Before requesting a quote, ask the hematology team to write down the stage, treatment plan, and endpoint being considered.
- Treating infections, bone problems, or kidney problems may add costs, but these do not happen to everyone. List planned costs separately from possible costs.
- A quote is an estimate, and a deposit is not the total cost. Obtain written confirmation of insurance, payment, cancellation, and refund terms from the organization responsible.
- If you develop new back pain with leg weakness, numbness, difficulty walking, or changes in bladder or bowel function, go to the nearest emergency department immediately and contact your treatment team. If you have a fever or other signs of infection, contact the hematology team immediately; if you cannot reach them or your condition is serious, go to the nearest emergency department. Do not delay care while waiting for a quote or travel arrangements.[1–2]
First, ask the hospital to state exactly what the quote covers
Give the receiving team your recent blood, urine protein, light chain, kidney function, bone marrow, pathology, and imaging reports, along with a timeline of previous treatment. Ask the doctor to explain what needs assessment or treatment now, which previous test results can be used, and which tests may need to be repeated. Give each hospital the same information and agree on the same starting point and endpoint—for example, “from the initial assessment to the end of the planned induction phase,” or “from preparation for cell collection to the agreed monitoring point after infusion.”[3]
Ask for the estimate to state the hospital and campus, assumed treatment plan and room type, currency, issue date and validity period, and specific inclusions and exclusions. If two totals cover different stages, numbers of cycles, or assumptions about complications, clarify those differences before comparing them. If the treatment plan or length of stay changes after assessment, ask the hospital to update the estimate.
Put the costs into one table
For each row, ask the hospital or relevant provider to enter the item, unit price and unit, estimated quantity, stage, subtotal, included/excluded/to be determined status, payment timing, and responsible party. Count items already included in a package only once. If the quantity or unit price is unknown, leave the subtotal pending confirmation. The table below is a checklist for requesting quotes; it does not mean every item is needed.
| Item | Who to ask and what to check |
|---|---|
| Diagnosis and reassessment | Hematology team and billing office: consultations, blood and urine tests, bone marrow and pathology review, flow cytometry or genetic testing, and which previous results can be used. Are specimen shipping and translation charged separately? |
| Imaging | Ask the doctor to explain the purpose of each scan and whether it needs repeating. Ask the billing office to specify the scan, number of scans, and whether contrast or reporting is included. Separate initial assessment from scans used to assess treatment response. |
| Anti-myeloma treatment | Ask the pharmacy and hematology team to list each medicine’s generic name, formulation, strength, route, frequency, expected number of cycles, and billing unit. Are administration, outpatient visits, or inpatient care charged separately? List maintenance treatment with its own time period. |
| Infection care and supportive care | Ask the doctor and billing office to list planned and conditional items separately: infection prevention and treatment, blood products, immunoglobulin, pain relief, bone protection, and related dental assessment; nephrology care, monitoring, or dialysis if there is kidney damage; and orthopedics, radiotherapy, or rehabilitation when needed. The doctor decides whether these are necessary.[3] |
| Autologous transplant, if planned | Ask the transplant team to list assessment, mobilization, collection, cell processing and storage, conditioning, infusion, room charges, and early recovery. How are additional collections, blood transfusions, or hospital stays for infection billed? |
| CAR-T, if planned | Ask the cell therapy team to list collection, manufacturing, bridging treatment, lymphodepletion, infusion, monitoring, and inpatient care. Check what the product price includes and how charges are settled if manufacturing fails, treatment is delayed, or infusion cannot take place. |
| Bispecific antibodies, if planned | List initial step-up dosing and observation, each subsequent dose, monitoring, and infection management. Use the same observation period when comparing with CAR-T. |
| Follow-up and returning home | List follow-up visits, blood or other tests, medicines, and prescribing within the agreed period. Ask the providers at the treatment location and at home separately. |
| Nonmedical expenses | Flights, local transport, accommodation, caregiver support, interpreting, coordination services, and rescheduling: confirm costs and change/refund terms with each actual provider. |
You can send the hospital this request: “For [the starting point and endpoint of this stage], assuming [the current treatment plan and room type], please itemize the unit price, unit, quantity, included items, unconfirmed items, and expected payment points. If [infection/additional collection, etc.] occurs, please list the charging method separately rather than including it in confirmed costs.”
How should medicines and cell therapies be priced?
The same medicine name may cover different formulations, strengths, and dosing frequencies. Ask the pharmacist whether billing is based on the amount actually used or on whole packs, and how the estimate will be updated if the dose or number of cycles changes. The price of one dose does not represent a full course. When comparing CAR-T with bispecific antibodies, include preparation and the same period of subsequent dosing and monitoring. If your actual prescription includes a belantamab mafodotin-related product, ask about eye assessments, follow-up visits, and additional costs if vision problems occur, based on the current prescribing information at the treatment location and your doctor’s instructions. Requirements in the US prescribing information do not establish availability in China.[7]
Confirm the specific product’s name, indication, regulatory jurisdiction, hospital supply, and your eligibility. For example, in 2023, China’s National Medical Products Administration conditionally approved Fucaso (equecabtagene autoleucel) for adults with relapsed or refractory multiple myeloma who met the prior-treatment requirements stated in the announcement. This describes that product’s approval in China at that time. It does not mean other CAR-T products are available, that every hospital can provide it, or that it is suitable for you. Ask the hospital and pharmacist to check the current prescribing information, supply, and charges.[4]
Check cash needs, insurance, and refunds before paying
Ask the hospital billing office to confirm the payment recipient, accepted payment methods, when the deposit is due, when it is credited against charges, and how the final bill is settled when you leave. Check interpreting or coordination service contracts separately with the service provider. Request itemized statements, payment receipts, and the final invoice. Cancellation, postponement, inability to proceed with infusion after collection, unused items, and remaining balances are governed by each provider’s written terms.
Ask your insurer to confirm in writing whether the specific hospital, medicines or cell product, inpatient care, complications, and follow-up after returning home are covered; whether prior authorization is required; coverage limits and deductibles; which costs qualify for direct billing; and the documents needed for claims. Then ask the hospital whether it accepts that insurer’s guarantee of payment and which costs you must pay upfront. Do not deduct unconfirmed reimbursement from the cash you need. You can divide the budget into “estimated total spending” and “cash needed before each payment point.” The deposit is part of total spending; do not add it twice. Update your cash records when insurance payments or refunds are actually received. When exchanging currency, record the exchange-rate date and fees.
If the quote involves a research study
First, ask the research team for the study name, registration number, hospital campus, and applicable regulatory pathway. Request the informed consent form and an itemized explanation of costs. Article 8 of China’s Regulations for the Implementation of the Drug Administration Law states that drug clinical trial sponsors and institutions must not charge participants fees related to the clinical trial.[5] Article 20 of China’s Regulations on the Administration of Clinical Research and Clinical Translation Applications of New Biomedical Technologies also states that sponsoring institutions and research institutions conducting clinical research covered by those regulations must not charge participants fees related to that clinical research. Article 27 separately addresses treatment and responsibility for costs when research causes harm to health.[8] Ask the research center and ethics committee to explain which pathway applies to the specific study and which costs are research-related. Do not infer this from the name “CAR-T” alone, and do not confuse clinical research with clinical translation applications or routine medical care. Responsibilities and written arrangements must be clear for screening, non-enrollment, research-related injury, care after withdrawal, travel and accommodation, and treatment after the study ends.
Taking part in research is voluntary. For research covered by China’s Measures for the Ethical Review of Life Science and Medical Research Involving Humans, participants or their guardians may withdraw unconditionally at any stage. Withdrawal does not depend on the research team’s agreement or completion of tests.[9] To support a safe transition in care, discuss stopping medicines, necessary follow-up, and subsequent treatment with the research doctor and your usual treating doctor. This is not a condition of withdrawal. Rules in other jurisdictions must be checked separately. Do not stop medicines on your own while waiting for screening. If you have questions about the basis for charges or the informed consent information, contact the research institution’s ethics committee.
What will you need to pay after returning home, and who will take over your care?
Before departure, ask the treatment team and your local doctor to agree on when follow-up visits should take place, who will review which results, whom to contact about abnormal findings, whether medicines are available locally, and who will prescribe them. Give the receiving doctor your treatment summary, medicine list, cell product or research information, test results, and follow-up plan. Ask both teams to estimate subsequent costs separately, including medicines, tests, remote consultations, translation, and return travel. Keep unconfirmed medicine supplies or costs marked as to be determined. The treatment team must also confirm how long you are expected to remain at the treatment location for observation, based on your individual circumstances.
Frequently asked questions
Can I compare quotes if the hospital gives only a total price?
First, request an itemized breakdown and the assumptions used. At a minimum, align the treatment stage, medicines, number of cycles, room type, and whether infection management is included. Ask for additional quotes for unclear items; do not count them as zero.
Can I multiply the cost of one test or one cycle to estimate a full year?
Only as a rough estimate based on stated assumptions. First, confirm that the frequency, strength or specification, and treatment plan will remain the same over that period. Ask the hospital to update the estimate if the plan changes or complications occur. Do not treat the result as a guaranteed price.
Will tests done elsewhere automatically save me the cost of repeat tests?
Not necessarily. Submit complete reports and images, and ask the receiving team whether they can use them and what additional tests are needed. List review or repeat-testing costs separately.
Will I need to pay more after paying a deposit?
Possibly. A deposit is not a price cap. Ask the billing office to explain in writing how it is credited, how you will be notified of additional payments, and how the final bill is settled. Keep your receipts.
If a medicine is on the medical insurance reimbursement list, can an overseas patient get reimbursed?
The list alone cannot establish this. Ask the insurer or medical insurance administrator to check your eligibility, the indication, the hospital, and settlement requirements, and obtain a specific answer.
Can I get a refund if the cells cannot be manufactured successfully or infusion cannot take place?
This depends on the product and hospital agreement. Before paying, request written details of costs incurred at each stage, amounts that may be refundable, required application documents, and who handles the request. Do not assume you will receive a full refund.
Who will continue my treatment if I fail research screening or withdraw early?
Before screening, ask your usual treating doctor and the research team to agree on an alternative care plan and how results will be handed over. Separately confirm costs already incurred and any follow-up tests that may be needed. The research team’s written response and the applicable rules together determine responsibility for costs.
Sources
Date checked: November 6, 2026. Specific treatment plans, prices, insurance coverage, and hospital acceptance are subject to written confirmation for your individual case and current rules.
-
US National Cancer Institute: Infection during cancer treatment.
-
US National Cancer Institute: Multiple myeloma treatment, patient version.
-
China’s National Medical Products Administration: Conditional approval announcement for Fucaso, 2023.
-
US National Cancer Institute: Informed consent and withdrawal from clinical trials.
-
US FDA: BLENREP patient information, 2025. US product information; separately check the current prescribing information at the treatment location and the actual prescription.
-
Regulations on the Administration of Clinical Research and Clinical Translation Applications of New Biomedical Technologies, Articles 20 and 27.
-
Measures for the Ethical Review of Life Science and Medical Research Involving Humans, Article 17.